Assistant Manager- CHRO's Office

This position is responsible for driving strategic people initiatives across geographies and businesses. The role works closely with the CHRO, HR leaders and business leaders to provide support across data backed decision making, global / large projects and manages the CHRO’s office.

Responsibilities:
Be the nodal point for all people related data and analytics. Help collate and analyse information for CHRO, HR leaders and Business leaders for decision making support
Plan, manage and drive global / large people related projects
Facilitate effective annual plans and regular reviews of ongoing / regular projects, actions, processes, etc for HR team across geography and business
Work with HR leaders to identify improvement areas, evaluate priorities and drive remediation processes wherever deemed necessary
HR MIS to CMD and other business leaders
Support compliance and reviews
Provide support for Corporate activities

External
Senior level candidates
Consultants and vendors

Internal (other than Direct Reports)
COG and other business / functional leaders
HR team leaders

DESIRED EXPERIENCE AND KNOWLEDGE

Educational Qualifications
MBA in Human Resources

Experience
2-3 years of HRBP experience

Knowledge and Skills (Functional / Technical)
Understanding the employee life cycle and events
Ability to communicate – articulation of issues and clarity of written expression
Analytical and data skills
Project management skills are a plus
Understanding of the organization and the pharma industry are desirable

Behavioural Attributes
Ability to influence and collaborate to get closure
Confidence and maturity to state a point of view and back it up with rationale
Perseverance and diligence

ABOUT GLENMARK

Glenmark Pharmaceuticals Ltd. is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com

INNOVATIVE MEDICINES GROUP
Innovation continues to be a key growth driver for Glenmark. In order to increase our focus on the in-house discovery and development of novel molecules, we have created a distinct sub-group within Glenmark called the “Innovative Medicines Group”. Through this division, we will continue the development of innovative therapies to address critical unmet medical needs and to improve the lives of patients and their families with serious diseases. Our current specialty pipeline consists of two respiratory molecules in various stages of clinical development, 1 molecule each in the therapy areas of pain and oncology. Each of these molecules has the potential to improve patient outcomes by proving to be safer and more effective than currently available therapies.
COMPANY AT A GLANCE